WA-AGC-BIOLOGICS
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new commercial manufacturing project at its Seattle protein biologics manufacturing site. The CDMO is producing TZIELD™ (teplizumab-mzwv), a new T1D treatment from Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated diseases.
Provention Bio chose AGC Biologics to manufacture TZIELD after the CDMO helped guide the product through PPQ manufacturing and validation batches, and United States Food and Drug Administration (FDA) approval. More than 1.8 million Americans have T1D, an autoimmune disease caused by the destruction of beta cells. TZIELD is the first and only immunomodulatory treatment that delays the onset of Stage 3 T1D in adult and pediatric patients aged 8 years and older. Patients who progress to Stage 3 T1D will eventually require insulin injections for life.
“The multi-year process of shepherding a new therapy from clinical research to commercial launch requires the collaboration of multiple partners, and we are grateful for the ongoing strategic collaboration of AGC Biologics as we begin to deliver TZIELD to patients,” said Provention Bio CEO Ashleigh Palmer. “This is an important milestone for the Type 1 Diabetes community, and we hope the launch of this therapy can truly make an impact on patients and families seeking innovative treatments for the delay of Stage 3 T1D.”
AGC Biologics runs multiple mammalian cGMP manufacturing lines and a variety of scales at its Seattle facility. The campus serves as a center of excellence for formulation and employs the latest fed-batch and perfusion manufacturing processes and houses a new microbial-based manufacturing line system. The AGC Biologics Seattle campus has produced biologics products for 30 years and has a long history of successful inspections by the FDA and commercial production.
“Congratulations to Provention Bio on this game-changing achievement for T1D patients,” said Kevin Ingham, General Manager of AGC Biologics’ Seattle site. “We at AGC Biologics are proud to have helped develop this innovative new medicine and to be manufacturing it for commercial distribution. This achievement demonstrates our Seattle site’s increasing track record in commercial manufacturing, which is aligned with AGC Biologic’s purpose of bringing hope to life.”
To learn more about AGC Biologics’ mammalian and microbial system-based biologics manufacturing site in Seattle, visit www.agcbio.com/facilities/seattle. For more information on the company’s Protein Biologics, Protein DNA (pDNA), Cell Therapy, Viral Vector and Messenger RNA (mRNA) drug product services visit www.agcbio.com.
About Provention Bio, Inc.
Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated diseases. The Company's pipeline includes clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in autoimmune diseases, including T1D, celiac disease and lupus. Visit www.ProventionBio.com for more information and follow us on Twitter: @ProventionBio.
About AGC Biologics
AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and we currently employ more than 2,000 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is the partner of choice. To learn more, visit www.agcbio.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230124005438/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lattice to Showcase its Latest FPGA Technology Innovations at the International VLSID Conference23.12.2025 01:50:00 CET | Press release
‒ Pravin Desale, Head of R&D, to Deliver Keynote on Growing Need for Low Power FPGAs ‒‒ Multiple Technical Sessions Focused on Edge AI, Sensor Fusion, System Design, and More ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced its exhibition plan for the upcoming International VLSID Conference taking place January 3 – 7, 2026 in Pune, India. As part of the event, Lattice Senior Vice President of Research and Development Pravin Desale will deliver a keynote presentation exploring the market dynamics and trends that are positioning low power FPGAs at the forefront of technological advancements. Lattice will also have track sessions and panel discussions on low power FPGAs and AI from edge to cloud, and technology demonstrations with industry partners focused on advanced automotive and robotics applications. Who: Lattice Semiconductor What / When (GMT+2): Lattice Demo Showcase (Major Stall #B1), Jan 5 – 7 Keynote Jan. 5, 10:30 – 11 a.m. at Main Audit
First Cessna SkyCourier Delivered into Mexico, Expanding Air Freight Capabilities for FlexCoah22.12.2025 18:13:00 CET | Press release
The first Cessna SkyCourier in Mexico was recently delivered to cargo transportation provider FlexCoah for use by the company’s aviation subsidiary, Altair. The aircraft — a freighter variant — will expand the company’s air freight capabilities throughout the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251222890759/en/ First Cessna SkyCourier delivered into Mexico, expanding air freight capabilities for FlexCoah (Photo Credit: Textron Aviation) The Cessna SkyCourier is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “The Cessna SkyCourier’s combination of reliability, payload capacity and mission flexibility makes it a powerful asset for operators looking to scale their operations while maintaining cost-efficiency,” said Lannie O’Bannion, senior vice president, Sales & Marketing. “The delivery of the Cessna SkyCourier to FlexCoah reflects the aircraft’s growing role in tran
Proudly Produced in Donegal: ProAmpac Invests in the Future of Food Board Manufacturing22.12.2025 17:34:00 CET | Press release
ProAmpac, a global leader in flexible packaging and material science, is strengthening its operational footprint with the expansion of Food Board manufacturing capabilities at its Donegal, Ireland campus. The addition of a new, purpose-built Food Board production area within the existing site reinforces ProAmpac’s commitment to innovation, efficiency, and customer service across the food packaging sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251222149380/en/ Carr & Sons Smoked Salmon - ProAmpac As an extension of the existing Donegal operations, which support the pet food, food-to-go, and CPG markets, the expanded production area increases capacity and precision. A state-of-the-art guillotine system delivers cleaner cuts and consistent board quality, ensuring every sheet meets ProAmpac’s performance standards. The expanded facility area introduces several key improvements for customers: Dedicated Customer Service T
Coherent Solutions closes strategic investment led by IceLake22.12.2025 16:07:00 CET | Press release
Coherent Solutions, a global digital engineering firm, has announced the closing of the strategic investment from IceLake, a leading private equity investor specializing in partnering with high-growth business services organizations. The transaction, previously announced in September 2025, has now received all necessary regulatory approvals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251222791182/en/ Coherent Solutions and IceLake close strategic investment Coherent Solutions employs ~2,000 digital engineering, product, and design professionals across Europe and Latin America. The company builds and modernizes digital products and platforms for growing scale-ups and established global brands. “In a market saturated with AI claims, we’re seeing clients prioritize partners who can convert technology into measurable business outcomes,” said Igor Epshteyn, CEO of Coherent Solutions. “Staying grounded in digital value creatio
China Industry Leaders Convene in Jianshui to Chart the Blueberry Sector’s Growth Path22.12.2025 14:32:00 CET | Press release
The Third Yunnan Blueberry Conference and the release ceremony of the “Xinhua–Yunnan Honghe Blueberry Industry Development Index Report” opened on December 19 in Jianshui County, Honghe Hani and Yi Autonomous Prefecture, in southwest China’s Yunnan Province. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251222516223/en/ The opening ceremony of the conference on 19th Dec in Jianshui. The conference has attracted scholars, experts, business representatives, and purchasers from across China, who have gathered here to explore pathways for promoting the high-quality development of the blueberry industry. During the three-day conference, organizers convened two major signing ceremonies: a cooperation agreement to jointly establish the Yunnan Blueberry Research Institute, and a strategic agreement to enhance financial support for the full industrial chain of Honghe blueberries. Outstanding organizations and individuals contributin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom